北米迷走神経刺激市場 – 業界動向と2029年までの予測

北米迷走神経刺激市場の分析と洞察

迷走神経は、代謝恒常性を調節する自律神経系の重要な構成要素であり、求心性および遠心性の経路を介して恒常性を維持する神経内分泌免疫軸の重要な構成要素として機能します。手動または電気刺激を含む迷走神経を刺激するあらゆるアプローチは、迷走神経刺激 (VNS) と呼ばれます。難治性てんかんおよび治療抵抗性うつ病の場合、左頸部 VNS は承認された治療法です。

WHO によると、神経疾患は世界中の全疾病の 4.5% ～ 11% を占めています。迷走神経刺激装置は、てんかん、 うつ病、喘息、心血管疾患を患う患者の治療にも使用されています。

北米の迷走神経刺激市場は、2022年から2029年の予測期間に成長すると予想されています。データブリッジマーケットリサーチは、市場は2022年から2029年の予測期間に18.0%のCAGRで成長し、2021年の2億7,717万米ドルから2029年には10億5,222万米ドルに達すると分析しています。

市場定義: 北米迷走神経刺激市場

The vagus nerve is a long cranial nerve that runs from a person’s brain stem into the neck, chest, and abdomen. It is a part of the parasympathetic nervous system, which is commonly referred to as the rest-and-digest system because it regulates body functions while a person is at rest. It delivers messages to a person’s brain from their digestive system and organs such as their lungs, heart, and liver. It controls several organ functions, including digestion, heart rate, and respiratory rate. It is responsible for vasomotor activity and reflexes. It also regulates vocalization, mood, and immunity. It influences sensory functions in a person’s ears, sinuses, and esophagus as well.

VNS involves a pulse generator inserted under a person’s skin on their chest. The implantable device, which is similar to a pacemaker, delivers regular electrical pulses to the brain via the vagus nerve. It is possible to provide additional stimulation by placing the provided magnet over the pulse generator. Relaxation techniques such as breathing exercises, yoga, and medication can influence vagus nerve activity, increasing its ability to relieve anxiety and mood-related symptoms. VNS can improve an individual’s physical health and can offer benefits for several conditions such as epilepsy and depression. The treatment has a healing effect on a person’s body due to its ability to promote relaxation and reduce inflammation.

Market Dynamics: North America Vagus Nerve Stimulation Market

Drivers

• Increasing prevalence and incidence of neurological disorders

Neurological disorders cause 4.5% to 11% of all illnesses, whether in low or high-income countries. The impact is greater compared to that of malignancies, gastrointestinal diseases, or respiratory illnesses, and it is expected to grow over the next years. In the U.S., neurological illnesses have also seen a significant rise, and over the next 20 years, this growth tendency is anticipated to continue. The prevalence of these neurological illnesses has been reported to range from 0.9% to 4% (970-4100 per 100,000 population), with an average of roughly 2.3% (2390 per 100,000 population). One of the most common neurological conditions, epilepsy, affects almost every country on earth. Most people with this illness are seen in high-population countries. Due to this rising prevalence, there is a rising demand for a variety of tools and treatments, such as VNS. More neurological problems are being treated with VNS. In addition to other clinical uses, it aids in the treatment of neurological conditions like epilepsy and depression due to the significant prevalence of neurological conditions worldwide.

• Innovative non-invasive vagus nerve stimulation devices introduced to meet demand

Traditional and conventional VNS devices are implanted in the patient's body and leads are placed on the vagus nerves that provide electrical stimulation when required. Growing demand and technological advancement of innovative devices lead to the introduction of small-sized implantable VNS devices in the market. These small-sized implantable devices offer various clinical benefits to patients and healthcare providers. The introduction of innovative devices is anticipated to boost the market growth.

Constant focus by market players to innovate and launch new products had led to the emergence of non-invasive VNS (nVNS) devices in the market. These devices are also known as transcutaneous VNS (tVNS) devices

• Rise in product approvals

The approval for VNS devices is governed by the U.S. FDA and the EU. The FDA issues a final protocol for filing a Pre-market Approval Application (PMA) or a notice of completion of a Product Development Protocol (PDP).

For instance,

• The FDA has approved an implantable vagus nerve stimulator to treat epilepsy and depression. In addition, in North America, new nVNS devices that do not require surgical implantation to treat epilepsy, depression, and pain have been approved.

The approval received for VNS devices would result in the device being declared safe to use and ready for post-marketing approval. It would result in the supply and distribution of MRI machines to the developing markets, situated in the North America region. Hence, the rise in product approvals is expected to propel market growth

• Product development in recent years

Combination Therapies are much more effective than monotherapy, without additional side effects. They are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieving patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A, and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.

Opportunities

• Strategic initiatives by the key market players

The demand for VNS devices is increasing in the market owing to the increased levels of R&D; along with that, the market growth is being aided by the desire for innovative medications. Thus, the top market players have implemented new strategies by developing new devices and equipment as well as collaborating with other players in the market and aimed at improving business operations and profitability.

The companies operating in the North America region in this market are adopting collaboration as a strategy to increase their product portfolio with advanced technology-rich products to boost their business in various dimensions. Thus, increasing strategic initiatives by key market players are expected to offer significant opportunities for market players operating in the market

• Rising government initiatives for neurological disease

The purpose of funding for VNS devices is to encourage applications seeking to develop devices for various neurological disorders. Novel devices should move beyond existing electrical or magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Therefore, the funding by the government would result in the safety of the patient and cost savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence, the advancements in R&D activities and funding by the government will act as an opportunity for this market growth.

Restraint/Challenge

• High maintenance and device costs to restrain adoption of vagus nerve stimulators

The rise in the cost of VNS devices is due to technological development and increased demand for nVNS devices by neurologists in hospitals, clinics, nursing facilities, and ambulatory surgical centers. Overhead costs can help explain why hospitals charge so much for stimulation devices. The increased intricacy and cost of VNS devices, technological innovations, and robust investments would increase the costs. The increased cost would result in delayed treatment of patients in hospitals and clinics. Hence, the increased cost of VNS devices is expected to restrain market growth.

Post-COVID-19 Impact on North America Vagus Nerve Stimulation Market

The COVID-19 outbreak had a drastic effect on North America healthcare with the U.S. being amongst the countries most severely impacted. The pandemic had a negative impact on the market growth, on account of a temporary halt in research activities in this field, coupled with the low influx of patients in hospitals and diagnostic centers.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the pharmacogenetics testing market.

Recent Development

• In May 2022, electroCore, Inc. announced that the gammaCore Sapphire non-invasive Vagus Nerve Stimulator will be available in 130 National Spine and Pain Centers (NSPC) affiliated locations across the U.S. for patients suffering from pain associated with different forms of primary headache. This would help the organization to develop more revenue.

North America Vagus Nerve Stimulation Market Scope

北米の迷走神経刺激市場は、製品タイプ、生体材料、用途、患者タイプ、エンドユーザー、流通チャネルに区分されています。これらのセグメントの成長は、業界のわずかな成長セグメントの分析に役立ち、ユーザーに貴重な市場概要と市場洞察を提供して、コア市場アプリケーションを特定するための戦略的決定を下すのに役立ちます。

製品タイプ

• 埋め込み型 VNS デバイス
• 外部 VNS デバイス

製品タイプに基づいて、市場は埋め込み型 VNS デバイスと外部 VNS デバイスに分類されます。

生体材料

• 陶芸
• メタリック
• ポリマー

生体材料に基づいて、市場はセラミック、金属、ポリマーに分類されます。

応用

• 疼痛管理
• てんかん発作
• 肥満管理
• うつ病と不安
• その他

用途に基づいて、市場は疼痛管理、てんかん発作、肥満管理、うつ病および不安症、その他に分類されます。

患者タイプ

• 大人
• 小児科
• 老年病

患者の種類に基づいて、市場は成人、小児、高齢者に分類されます。

エンドユーザー

• 病院
• 外来手術センター
• 専門センター
• その他

エンドユーザーに基づいて、市場は病院、外来手術センター、専門センター、その他に分類されます。

流通チャネル

• 直接入札
• 小売販売
• その他

流通チャネルに基づいて、市場は直接入札、小売販売、その他に分類されます。

北米迷走神経刺激市場の地域分析/洞察  

北米の迷走神経刺激市場が分析され、市場規模の洞察と傾向が、上記のように国、製品タイプ、生体材料、用途、患者タイプ、エンドユーザー、流通チャネル別に提供されます。

米国は、市場シェアと収益の面で北米の迷走神経刺激市場を支配しており、予測期間中もその優位性を維持し続けるでしょう。これは、この地域における神経疾患の有病率と発症率が高いことによるもので、研究開発投資の増加と新製品の発売が市場の成長を後押ししています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。新規および交換販売、国の人口統計、疾病疫学、輸出入関税などのデータ ポイントは、個々の国の市場シナリオを予測するために使用される主要な指標の一部です。さらに、国別データの予測分析を提供する際には、北米ブランドの存在と可用性、地元および国内ブランドとの競争により直面する課題、販売チャネルの影響が考慮されています。

競争環境と北米の迷走神経刺激市場シェア分析

北米迷走神経刺激市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、北米でのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、市場に関連する会社の焦点にのみ関連しています。

この市場で活動している主要企業としては、Medtronic、LivaNova PLC、electroCore, Inc.、Cirtec、Brain Control Co. Limited、Soterix Medical Inc.、SetPoint Medical、MicroTransponder Inc、Parasym Ltd、tVNS Technologies GmbH などがあります。

研究方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。市場データは、市場統計モデルとコヒーレント モデルを使用して分析および推定されます。さらに、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数の市場への影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、企業市場シェア分析、測定基準、北米と地域、ベンダー シェア分析が含まれます。さらに質問がある場合は、アナリストへの電話をリクエストしてください。

SKU-69407